Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio-TechneTECH -0.24%87 Days Sales Outstanding is 61.24 as of Jun. 2026, which is 7% below its 10-year median of 66.10. GuruFocus rates TECH with a GF Score™ of 87/100 and a GF Value™ of $71.19 (Fairly Valued). The stock has 7 warning signs investors should review. Among 841 Biotechnology companies, Bio-Techne ranks better than 55.65% on this metric.
Bio-Techne's average Accounts Receivable for the
three
months ended in Jun. 2026 was $216 Mil. Bio-Techne's Revenue for the
three
months ended in Jun. 2026 was $321 Mil.
Hence, Bio-Techne's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 61.24.
The historical rank and industry rank for Bio-Techne's Days Sales Outstanding or its related term are showing as below:
TECH'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 52.52 Med: 66.1 Max: 72.41
Current: 60.47
During the past 13 years, Bio-Techne's highest Days Sales Outstanding was 72.41. The lowest was 52.52. And the median was 66.10.
TECH's Days Sales Outstanding is ranked better than 55.65% of 841
companies
in the Biotechnology industry
Industry Median: 68.94
vs TECH: 60.47
Bio-Techne's Days Sales Outstanding
declined
from Jun. 2025 (63.91) to Jun. 2026 (61.24).
Bio-Techne (NAS:TECH) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Bio-Techne Days Sales Outstanding Related Terms
Bio-Techne Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Bio-Techne's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TECH vs SMMT, HALO, ARWR: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Bio-Techne's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Techne Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bio-Techne's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Bio-Techne's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Techne (TECH) has a Days Sales Outstanding of 61.24 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Bio-Techne and its competitors. This is near median its historical median of 66.10. Over the past decade, Bio-Techne's Days Sales Outstanding has ranged from 52.52 to 72.41. According to the industry distribution chart, Bio-Techne ranks #373 out of 841 companies in the Biotechnology industry, placing it in the top 44.4%.
Is Bio-Techne's Days Sales Outstanding too high?
Bio-Techne's current Days Sales Outstanding of 61.24 is near median its 10-year median of 66.10. Over the past 10 years, this metric has ranged from a low of 52.52 to a high of 72.41. The Biotechnology industry median Days Sales Outstanding is 68.94. Bio-Techne's value of 61.24 is 11.2% below this industry median. Based on the distribution chart, Bio-Techne ranks #373 out of 841 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Bio-Techne has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bio-Techne's Days Sales Outstanding compare to SMMT and HALO?
According to the Biotechnology industry distribution chart, Bio-Techne ranks #373 out of 841 companies for Days Sales Outstanding. This puts Bio-Techne in the upper half of its industry. The industry median Days Sales Outstanding is 68.94. Bio-Techne's value of 61.24 is 11.2% below this benchmark. Historically, Bio-Techne's own Days Sales Outstanding has ranged from 52.52 to 72.41 over the past decade. While the company's 10-year median is 66.10 vs. the industry median of 68.94, Bio-Techne has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.94, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio-Techne's current Days Sales Outstanding of 61.24 is 11.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Bio-Techne and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio-Techne's current Days Sales Outstanding is 61.24, which is near median its own 10-year median of 66.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Techne stock overvalued right now?
Based on GuruFocus' analysis, Bio-Techne (TECH) is currently considered Fairly Valued. The stock's GF Value™ is $71.19, compared to a current price of $72.08 — trading 1.3% above its estimated fair value. The current Days Sales Outstanding is 61.24, which is near median its 10-year median of 66.10 and 11.2% below the Biotechnology industry median of 68.94. Bio-Techne's overall GF Score™ is 87/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Bio-Techne (TECH), the current Days Sales Outstanding is 61.24 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio-Techne (TECH) Overvalued in 2026?
Based on GuruFocus' analysis, Bio-Techne stock appears to be overvalued.
The current stock price of $72.08 is trading 1.3% above its estimated GF Value™ of $71.19.
GuruFocus considers Bio-Techne to be Fairly Valued.
Key valuation signals for TECH:
Days Sales Outstanding: 61.24 (near median its 10-year median of 66.10)
GF Value™: $71.19 vs. price of $72.08 (1.3% above fair value)
Industry Position: 11.2% below the Biotechnology median (#373 of 841)
No single metric tells the full story. See the TECH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
87GF Score
Get the complete analysis for TECH
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TECH has been successfully added to your 
